| |
IND-enabling nonclinical studies play a crucial role in bringing new medications to market. But these tests require careful coordination & meticulous execution. Read our 5-step checklist to help make sure the data is accepted by regulatory agencies. Attending ACT Nov 12-15? Schedule a meeting with our experts!
|
|
Today’s Big NewsSep 27, 2023 |
| By Nick Paul Taylor AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with Caribou, depriving the biotech of the chance to pocket up to $350 million in milestones per program. |
|
|
|
By Nick Paul Taylor Gilead’s $4.9 billion immuno-oncology bet has suffered another setback. An ad hoc analysis of a phase 3 leukemia trial found the anti-CD47 antibody is unlikely to improve survival, prompting the Big Biotech to stop the study. |
By Annalee Armstrong Ginkgo Bioworks has snared one of its biggest partners to date. The biology biotech will work with none other than Pfizer in a drug discovery deal for RNA medicines worth $331 million in biobucks for three programs. |
Sponsored by IPM.ai IPM.ai helps brands assess a unique patient population, accelerate clinical trial recruitment, and optimize commercial outcomes |
By James Waldron When Roche’s gantenerumab failed a pair of phase 3 studies last year, the pharma giant said it would look for “external collaborations and partnerships” as an avenue to treat Alzheimer’s disease. With today’s agreement with longtime partner Ionis, it seems the drugmaker is sticking to its word. |
Sponsored by Emulate An introduction to Organ-on-a-Chip technology and how it can improve the quality of drugs entering the clinic. |
By James Waldron A month after halting work on an inhaled treatment for idiopathic pulmonary fibrosis in the wake of a phase 2 trial fail, Galecto is laying off 70% of its workforce as the Boston-based biotech mulls its options. |
By Gabrielle Masson In a reversal of fortunes, ProQR Therapeutics’ ophthalmology asset sale to Laboratoires Théa has been cancelled after ProQR failed to meet conditions of the deal. |
By James Waldron Evommune has dropped its only clinical-stage asset after reviewing data from a phase 2 trial in atopic dermatitis. |
By Annalee Armstrong Patients with wet age-related macular degeneration who added Unity Biotechnology’s retinal disease med on top of Regeneron’s Eylea maintained their vision gains achieved with the blockbuster approved therapy alone—but they didn’t experience any major gains that the biotech was hoping for. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Kevin Dunleavy A Massachusetts federal judge has sided with Eli Lilly, overturning a $176.5 million jury verdict from November of last year. The verdict had been awarded to Teva in a patent infringement squabble over the companies’ competing migraine drugs. |
By Conor Hale Dubbed BigRNA, Deep Genomics' neural network is designed to predict the how RNA expression is regulated tissue-by-tissue, to better understand how variants in genes ultimately give rise to disease. |
By Paige Minemyer Virgin Pulse and benefits administrator HealthComp are set to merge in a $3 billion deal that aims to drive lower costs and improve outcomes for employers. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "Podnosis," Heather Landi from Fierce Healthcare engages in a conversation with Othman Laraki, co-founder and CEO of Color Health. They delve into strategies for boosting screenings and explore the partnership between Color Health and the American Cancer Society, aimed at making convenient cancer screenings more accessible. |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Time is running out, be left out! Register today
|
|
| Whitepaper As the field of real-world data and evidence is constantly evolving, it can be hard to keep-up with best practices. Do you know the definitive characteristics of a high-quality dataset? What questions to ask if you decide to outsource your research to consultants? Here’s everything you need to know in one, must-have guide. Sponsored by: MarketScan by Merative |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
